Navigation Links
NxStage Names Todd M. Snell Senior Vice President of Quality Assurance, Regulatory & Clinical Affairs
Date:9/10/2012

LAWRENCE, Mass., Sept. 10, 2012 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced Todd M. Snell has joined the Company as Senior Vice President of Quality Assurance, Regulatory & Clinical Affairs.

(Logo:  http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

"NxStage has a strong culture of compliance and tradition of high quality and excellence in delivering renal products to patients and customers worldwide," said Jeffrey H. Burbank, President and CEO of NxStage Medical. "Todd will play a significant role in our future growth and success as we seek to advance multiple products through clinical and regulatory processes."

"NxStage's ongoing innovation in renal care makes them a leader in the industry," said Todd Snell. "I am excited to join the NxStage team and look forward to helping advance NxStage's ongoing commitment to quality and excellence."

Snell brings to NxStage more than 20 years of quality and operational leadership experience with over 13 years in the healthcare industry, overseeing quality assurance and compliance for vascular care products, rare disease treatments and other therapeutic areas. Most recently, Snell served as the Vice President of Quality Assurance, Regulatory Affairs for Vascular Therapies at Covidien. Other previous positions include Vice President of Quality and Regulatory Compliance at Genzyme Corporation and Quality Systems Leader at GE Medical Systems. Prior to his work in healthcare, Snell served as a Captain in the United States Army.

Mr. Snell received his BS in Systems Engineering from the United States Military Academy (West Point, NY) and his MBA in Operations Management from University of Colorado (Colorado Springs).

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ES RD, and acute kidney failure. NxStage is leading the development of the home dialysis market in the US with the only portable dialysis machine, the System One™, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2012. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Kristen K. Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com

 


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
2. NxStage Patient and Advocate Brian Hess Receives Prestigious Honor from American Association of Kidney Patients
3. NxStage to Present at the Canaccord Genuity 32nd Annual Growth Conference
4. NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2012
5. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
6. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
7. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
8. H. D. Smith Names Timothy Booth Corporate VP, Home Healthcare (HHC), In First-of-its-Kind Leadership Appointment
9. Imprimis Names Two Experts To Its Science And Regulatory Board
10. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
11. BioMotiv Names New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
Breaking Medicine News(10 mins):